Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents

Journal of Clinical Pharmacology

Volumn 36, Issue 9, 1996, Pages 783-791

  Von Moltke, Lisa L ^a,b   Greenblatt, David J ^a,b   Schmider, Jürgen ^a,b   Duan, Su Xiang ^a,b   Wright, C Eugene ^c   Harmatz, Jerold S ^a,b   Shader, Richard I ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; BENZODIAZEPINE DERIVATIVE; CYTOCHROME P450; DRUG METABOLITE; FLUCONAZOLE; FLUOXETINE; ITRACONAZOLE; KETOCONAZOLE; MIDAZOLAM; NORFLUOXETINE; PYRROLE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG STRUCTURE; DRUG TRANSFORMATION; HUMAN; HUMAN TISSUE; LIVER MICROSOME; METABOLIC INHIBITION; MICHAELIS MENTEN KINETICS; MODEL;

EID: 0029743080     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04251.x     Document Type: Article

References (59)

1. Reves JG, Fragen RH, Vinik HR, Greenblatt DJ: Midazolam: pharmacology and uses. Anesthesiology 1985;62:310-324.
2. Dundee JW, Halliday NJ, Harper KW, Brogden RN: Midazolam: a review of its pharmacological properties and therapeutic use. Drugs 1984;28:519-543.
3. Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M: Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 1992;51:715-728.
4. 14C-midazolam in humans following oral dosing. Arzneimittelforschung 1981;31:2220-2223.
5. Heizmann P, Eckert M, Ziegler WH: Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol 1983;16: 43S-49S.
6. Arendt RM, Greenblatt DJ, Garland WA: Quantitation by gas chromatography of the 1- and 4-hydroxy metabolites of midazolam in human plasma. Pharmacology 1984;29:158-164.
7. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA: Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989;36:89-96.
8. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA: Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994;47:1643-1653.
9. Wrighton SA, Ring BJ: Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharm Res 1994;11: 921-924.
10. Wandel C, Böcker R, Böhrer H, Browne A, Rügheimer E, Martin E: Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth 1994;73:658-661.
11. Olkkola KT, Backman JT, Neuvonen PJ: Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55:481-485.
12. Ahonen J, Olkkola KT, Neuvonen PJ: Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol 1995;40: 270-272.
13. Olkkola KT, Ahonen J, Neuvonen PJ: The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 1996;82:511-516.
14. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg J-J, Neuvonen PJ: A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993;53:298-305.
15. Backman JT, Olkkola KT, Neuvonen PJ: Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996;59:7-13.
16. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI: Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994;268:1278-1283.
17. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI: Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994;38:23-31.
18. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI: In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol 1994;34:1222-1227.
19. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI: Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995;15:125-131.
20. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI: Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin-reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol 1996;16:104-112.
21. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, et al: Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996;276:370-379.
22. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI: N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors. J Pharmacol Exp Ther 1995;275:592-597.
23. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Duan SX, Karsov D, Shader RI: Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies. Pharmacology 1996;52: 125-134.
24. Segel IH: Enzyme Kinetics. New York: Wiley, 1975.
25. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI: Metabolism of drugs by cytochrome P450-3A isoforms: implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995;29(Suppl 1):33-43.
26. Heykants J, Michiels M, Meuldermans W, Monbaliu J, Lavrijsen K, Van Peer A, et al: The pharmacokinetics of itraconazole in animals and man: an overview. In, Fromtling JR (ed.): Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Barcelona: J. R. Prous Science Publishers, S. A., 1987;223-249.
27. Gascon M-P, Dayer P: In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 1991;41:573-578.
28. Ring BJ, Binkley SN, Roskos L, Wrighton SA: Effect of fluoxetine, norfluoxetine, sertraline and desmethylsertraline on human CYP3A catalyzed 1′-hydroxy midazolam formation in vitro. J Pharmacol Exp Ther 1995;275:1131-1135.
29. Ferslew KE, Hagardorn AN, McCormick WF: Postmortem determination of the biological distribution of sufentanil and midazolam after an acute intoxication. J Forensic Sci 1989;34:249-257.
30. Scavone JM, Friedman H, Greenblatt DJ, Shader RI: Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. Arzneimittelforschung 1987;37:2-6.
31. Wong RJ: The determination of the triazolobenzodiazepine triazolam in post mortem samples. J Anal Toxicol 1984;8:10-13.
32. 14C-diazepam and its metabolites in rats. Drug Metab Dispos 1982;10:676-679.
33. Bornemann LD, Min BH, Crews T, Rees MMC, Blumenthal HP, Colburn WA, Patel IH: Dose dependent pharmacokinetics of midazolam. Eur J Clin Pharmacol 1985;29:91-95.
34. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, et al: Use of midazolam as a human cytochrome P450 3A probe. I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994;271:549-556.
35. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE, et al: Use of midazolam as a human cytochrome P450 3A probe. II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 1994;271:557-566.
36. Hargreaves JA, Jezequel S, Houston JB: Effect of azole antifungals on human microsomal metabolism of diclofenac and midazolam. Br J Clin Pharmacol 1994;38:175P.
37. Back DJ, Tjia JF: Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 1991;32:624-626.
38. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB: Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-1878.
39. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR: Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996;59:491-502.
40. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ: The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995;58:15-19.
41. Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krähenbühl S: Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995;58:20-28.
42. Ducharme MP, Warbasse LH, Edwards DJ: Disposition of intravenous and oral cyclosporine after administration with grape-fruit juice. Clin Pharmacol Ther 1995;57:485-491.
43. Como JA, Dismukes WE: Oral azole drugs as systemic antifungal therapy. New Engl J Med 1994;330:263-272.
44. Bailey EM, Krakovsky DJ, Rybak MJ: The triazole antifungal agents: a review of itraconazole and fluconazole. Pharmacotheropy 1990;10:146-153.
45. Debruyne D, Ryckelynck J-P: Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet 1993;24:10-27.
46. Vanakoski J, Mattila MJ, Vainio P, Idänpään-Heikkilä JJ, Törnwall M: 150 mg fluconazole does not substantially increase the effects of 10 mg midazolam or the plasma midazolam concentrations in healthy subjects. Int J Clin Pharmacol Ther 1995;33:518-523.
47. Rasmussen BB, Mäenpää J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J, Brøsen K: Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995;39:151-159.
48. Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS: Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992;52:479-486.
49. Lasher TA, Fleishaker JC, Steenwyk RC, Antal EJ: Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology 1991;104:323-327.
50. El-Yazigi A, Chaleby K, Gad A, Raines DA: Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. J Clin Pharmacol 1995;35:17-21.
51. Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF: The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther 1988;43:412-419.
52. Grimsley SR, Jann MW, Carter JG, D'Mello AP, D'Souza MJ: Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 1991;50:10-15.
53. Bergstrom RF, Peyton AL, Lemberger L: Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992;51:239-248.
54. Levine B, Jenkins AJ, Smialek JE: Distribution of sertraline in postmortem cases. J Anal Toxicol 1994;18:272-274.
55. Bailey DN, Shaw RF: Interpretation of blood and tissue concentrations in fatal self-ingested overdose involving amitriptyline: an update (1978-1979). J Anal Toxicol 1980;4:232-236.
56. Tucker GT: The rational selection of drug interaction studies: implications of recent advances in drug metabolism. Int J Clin Pharmacol Ther Toxicol 1992;30:550-553.
57. Boobis AR: Prediction of inhibitory drug-drug interactions by studies in vitro. In, Pacifici GM, Fracchia GN (eds.): Advances in Drug Metabolism in Man. Luxembourg: the European Commission, 1995;513-539.
58. Leemann TD, Dayer P: Quantitative prediction of in vivo drug metabolism and interactions from in vitro data. In, Pacifici GM, Fracchia GN (eds.): Advances in Drug Metabolism in Man. Luxembourg: the European Commission, 1995:783-830.
59. Wright CE, Lasher-Sisson TA, Steenwyk RC, Swanson CN: A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine. Pharmacotherapy 1992;12:103-106.